{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["BHV-1530"],["BHV-1530","cemiplimab"]],"indication":"advanced or metastatic solid tumors","name":"NCT06874335","nct_id":"NCT06874335","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06874335. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"BHV-1530 Monotherapy","type":"EXPERIMENTAL"},{"description":null,"label":"Experimental: BHV-1530 in combination with Cemiplimab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-03","type":"ESTIMATED"},"conditions":["Solid Tumor"],"enrollment":{"count":140,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"BHV-1530","otherNames":["AMB302"],"type":"DRUG"},{"name":"Cemiplimab","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-09","lead_sponsor":"Biohaven Therapeutics Ltd.","official_title":"A Phase 1, Multicenter, Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination With Other Anti-Cancer Agents in Adult Participants With Advanced or Metastatic Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2029-03","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Dose-escalation and Dose-expansion Cohorts: To determine the safety profile, maximum tolerable dose (MTD), minimally reproducible active dose (MRAD), and recommended dose range (RDR) of BHV-1530 monotherapy and BHV-1530 in combination with cemiplimab","timeFrame":"Through study completion, estimated as an average of 48 months"},{"measure":"Dose-optimization Cohorts: Recommended dose of BHV-1530 for later phase trials","timeFrame":"Through study completion, estimated as an average of 48 months"}],"references":[],"start_date":{"date":"2025-03-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 1 Study of BHV-1530 in Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT06874335"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06874335"}